Good morning, everyone. So I’m going to talk about selinexor in combination with ruxolitinib, and these are my relevant disclosures. I’ve highlighted my role as a steering committee member for the Karyopharm study I’m going to discuss, as well as support from Karyopharm to conduct the study at Yale.
So we will talk about selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: the Phase III SENTRY study. This was presented in June extensively. John presented at ASCO, Claire presented at EHA, and there was a publication in JCO. This is the 24-week primary data for this study.
But first of all, why are we looking at this combination? So the preclinical studies identified the potential for cooperation between the JAK inhibitor ruxolitinib and the XPO1 inhibitor selinexor. So XPO1 carries cargo proteins, which are listed on the right, including some which may be important in the biology of myelofibrosis, including TP53, which is important for many malignancies. And so keeping these proteins inside the nucleus may have benefit, decreasing malignant cell proliferation and increasing malignant cell death.
So this drug has been approved for the management of myeloma, relapsed/refractory myeloma, where it is used at higher doses than in the study I’m going to talk about: 80 milligrams twice a week, or 100 milligrams weekly. Our myeloma colleagues are telling me that they are not using this drug at those doses anymore. It was also used in relapsed/refractory diffuse large B-cell lymphoma, but that approval was withdrawn as the company decided not to further explore use of this medication for lymphomas, where there are a lot of drugs being developed.
So, as I said, the preclinical studies showed that these drugs may cooperate, and in addition to increased malignant cell death and decreased malignant cell proliferation, XPO1 inhibition with selinexor may attenuate the JAK-STAT pathway together with ruxolitinib, as well as inhibit the NF-κB pathway, which may be important in myelofibrosis.
So the Phase I study showed promising results, and we moved on to the Phase III SENTRY trial, where patients were randomized two to one to receive selinexor at a dose of 60 milligrams weekly, with obligatory antiemetic premedication, taking into consideration the side-effect profile of this drug, for the first two cycles, which were 28-day cycles. And randomization was against placebo plus ruxolitinib. So the inclusion criteria were pretty much the same as for other studies; I just want to highlight that the platelet count should be 100 or higher. And the co-primary endpoints of the study are SVR35 at week 24, as well as absolute change in TSS. The results were presented for select secondary endpoints, including overall survival and safety, and a select exploratory endpoint, which is VAF reduction. I’m going to go over this in the next few slides.
So patient disposition and treatment exposure were similar between the arms. What I want to highlight here is that the adverse events leading to discontinuation were similar in both arms, 9% and 8.6%. Withdrawal by patient was a little bit more frequent, 11% versus 2.6%. And transformation to AML was the same, 1.7% in both arms. And the median daily ruxolitinib dose was lower in patients receiving selinexor plus ruxolitinib. So baseline characteristics were well balanced. One thing to highlight here is that more than half of the patients in both arms had intermediate-1 risk disease.
So this is one part of the co-primary endpoint, SVR35 at week 24, and as you can see, it was significantly higher with selinexor plus ruxolitinib versus ruxolitinib alone, almost double: 50% versus 28%. So looking further at spleen responses, the spleen response was deep, rapid and sustained. You can see the responses occurred by week 12 in most of the patients, and you can also see that by week 36, about 47% of patients had an SVR35 response on the selinexor arm, and 23% in the placebo plus ruxolitinib arm. So looking at subgroup analysis for SVR35, the benefit was observed across pre-specified subgroups, including patients with bigger spleens and smaller spleens.
And there was no difference in absolute TSS, which is the other co-primary endpoint in the study. Numerically, you can see that it was a little less in selinexor plus ruxolitinib than in the placebo plus ruxolitinib arm.
So the one highlight of this study, when compared to what Rajiv just presented and other studies, is that there was a meaningful overall survival improvement in selinexor plus ruxolitinib versus ruxolitinib alone. And so, of course, the observation period is about 12 months, and the number of events is limited: the total number of events is 23. So this is preliminary, but an exciting observation.
So we’ll look at this analysis, which is looking at what happened to those patients who had an SVR35 response at week 24. So this response predicted overall survival irrespective of treatment. So patients who were treated with or without selinexor and accomplished this goal at week 24 had better overall survival based on this analysis. And this is consistent with previous observations, post hoc analyses of the COMFORT studies, as well as multiple real-world studies which were discussed yesterday by John during his presentation.
So this is one of the exploratory analyses, specifically driver mutation VAF reduction by 20% or higher, which was seen in a higher number of patients treated with selinexor: this is 32 versus 24%. And this VAF reduction of 20% or higher was associated with a higher likelihood of achieving SVR35.
So this is an interesting observation. This is pointing towards selinexor as an efficacious agent by itself, right? So it works pretty well with ruxolitinib, but at a very low dose. If you look at the leftmost column, you can see that there was no SVR35 response among patients who were treated with low-dose ruxolitinib. As we know, it doesn’t really work well when you give it at a low dose, so this is a dose of less than 15 milligrams a day. But you still see a 50% SVR35 response among patients who were treated with a combination of low-dose ruxolitinib and selinexor.
So, again, some post hoc analysis of blast count. On the left, you can see patients who had circulating blasts at the time of enrollment on the study, and what happened to them, separated by the two treatment arms. And you can see that by the end of the observation period, a reduction of blasts was observed more frequently among patients who were treated with selinexor. On the right, you see patients who didn’t have blasts circulating in the blood at the time of treatment initiation. And again, patients who were treated with selinexor had fewer blasts at the time when observation ended.
So the safety profile was manageable and consistent with the known profiles of both agents, and serious adverse events were similar in both arms. So we discussed that there were more adverse events leading to treatment discontinuation among selinexor-treated patients, 14.5% versus 8.6%. But deaths were similar in both arms. So this is treatment-emergent adverse events, and you can see that patients treated with selinexor plus ruxolitinib had more hematologic adverse events and more GI adverse effects, including nausea and diarrhea. But overall, this was pretty balanced otherwise. The transformation to acute myeloid leukemia was rare and equivalent between arms, 1.7% each.
So before I move on to a discussion, I want to mention the SENTRY-2 Phase II trial, and this is the design of the study. This is looking at selinexor single-agent treatment in newly diagnosed, untreated patients with myelofibrosis, and the study design allows different JAK inhibitors to be added. By week 12, if SVR is less than 10%, or by week 24, if SVR is less than 35%, ruxolitinib is added if you have a decent amount of platelets and hemoglobin more than 10, pacritinib if the platelet count is less than 50, and momelotinib if the platelet count is more than 50 but hemoglobin is less than 10. Initially, the study was designed to include patients who have a platelet count less than 100, but due to poor enrollment, that upper limit was removed in 2025. So this study has two arms: selinexor 60 mg in arm 1 and selinexor 40 mg in arm 2. And as far as I know, arm 1 completed accrual and arm 2 is almost finished with accrual. And I know that results for arm 1 will be presented at ASH. So it’s exciting to see what selinexor can do on its own. We do have a signal that it works pretty well for patients who are only on a low dose of ruxolitinib.
So finally, discussion. So SENTRY demonstrated a robust spleen response, about 50% versus 28% at week 24, and SVR35 was associated with improved survival. So several questions remain. So the co-primary endpoint was not met; this is absolute TSS, which is consistent with other studies of add-on treatments to ruxolitinib in the frontline setting. But the reduction was similar in both arms, ruxolitinib monotherapy and ruxolitinib plus selinexor. Overall survival data remain immature, and we can see that it is based on 23 deaths and a median follow-up of about 12 months. Toxicity was greater with the combination, including hematologic and GI. And the question remains: is SVR35 alone sufficient evidence of clinical benefit, and can it serve as a surrogate for survival? And ultimately, it is about disease modification. So is there a modification of the underlying disease biology with this XPO1 plus JAK inhibition?
So what are the next steps? A supplemental NDA was submitted to the FDA at the end of August, and the company, Karyopharm, requested accelerated approval with priority review. And we are looking forward to hearing updates at ASH 2026 based on the patients who reached week 48 or discontinued prior to week 48. So I think the company is in negotiation with the FDA about the sNDA submission, and I’m not sure how soon we’ll see updates on overall survival, but certainly this is the key to this drug’s approval. So we will hear about exploratory endpoints, including driver mutation VAF, fibrosis-grade improvement and plasma cytokines. And it will be interesting to see the presentation on SENTRY-2, mostly arm 1 and, at some point, arm 2 data.
So, if we want to be more provocative, we can talk a little bit about potential clinical positioning. If this drug is approved, it is closest to that point among others. And the question is, should we give it to everyone if it is approved? I think if we keep in mind the splenomegaly benefit, we may consider it for those where maximizing spleen response is a priority. One example would be patients who are going to transplant. It’s particularly interesting when ruxolitinib dose intensity may be limited, right? So we saw the signal that selinexor works on its own with little ruxolitinib. And it’s less compelling when symptom improvement is the dominant treatment goal. Of course, long-term use will depend on tolerability and confirmation of survival and disease-modifying benefit. Thank you.
AI-generated transcript. Please refer to the video as the authoritative source.